Skip to main content
OpenTrials
Completed

NCT Number: NCT06129318

:Effects of Pharmaceutical Care in Stroke Patients

To evaluate the effects of the 1-year pharmaceutical care program offered by the clinical pharmacist to the patients admitted to the neurology service with the diagnosis of stroke, on medication adherence, quality of life, and clinical outcomes of the patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Nervous System Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Marmara University Pendik Research and Training Hospital

Istanbul, Turkey (Türkiye)

About this study

The study was conducted as a parallel randomized controlled study in the Neurology Clinic of a University Hospital in Turkey. Patients were randomly assigned to intervention and usual care groups. While the patients in the usual care group are given routine health services by the neurologist during their hospitalization and for 1 year after discharge; In addition to these routine services, the intervention group was provided with pharmaceutical care by a clinical pharmacist during the same period. The study was always conducted by the same neurologist and clinical pharmacist. Patient medication adherence, quality of life, and clinical parameters were evaluated at the beginning of the study and at the 12th month.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • being diagnosed with stroke,
  • being 18 years old or older,
  • being in the cognition to receive the training to be given

Exclusion criteria

  • Not having adequate cognitive function such as dementia,
  • being pregnant, lactating,
  • having cancer.

Treatment and study plan

Clinical Pharmacist Led Pharmaceutical Care

Behavioral

Within the scope of pharmaceutical care, medication review services for past and current medication use were provided by the clinical pharmacist. The patients in the intervention group were given verbal information about the definition of stroke, symptoms, how to manage risk factors, and their medications by the clinical pharmacist on the day of discharge, in addition to the neurologist. Each patient in the intervention group had a scheduled meeting with the clinical pharmacist. During the 1-year follow-up the patient education given by the clinical pharmacist was repeated every 3 months.

Primary outcomes

  1. Blood pressure

    Time frame: 1, 3, 6, 9 and 12 months

    Blood pressure was checked and recorded by a qualified nurse during the hospital stay and at control visits. Measurements were recorded as mmHg.

  2. Medication Adherence

    Time frame: 3, 6, 9 and 12 months

    Adherence to Stroke Prevention Medications (Anti platelets, Anticoagulants, Statins, antihypertensives, antidiabetics) measured by Morisky-Green-Levine Adherence Scale (1-4) where higher scores indicate higher levels of reported adherence.

  3. HbA1c

    Time frame: 1, 3, 6, 9 and 12 months

    HbA1c (glycated hemoglobin) value was collected from medical records and recorded as a percentage.

  4. LDL cholesterol

    Time frame: 1, 3, 6, 9 and 12 months

    Low density lipoprotein-cholesterol level was collected from medical records and recorded as mg/dL

  5. Triglyceride

    Time frame: 1, 3, 6, 9 and 12 months

    Triglyceride level was collected from medical records and recorded as mg/dL.

  6. Body mass index

    Time frame: 1, 3, 6, 9 and 12 months

    Body mass index (BMI) was collected from medical records and recorded as kg/m2

Secondary outcomes

  1. Measuring Quality of Life

    Time frame: 3, 6 and 12 months

    The patients' quality of life was evaluated using the Stroke-Specific Quality of Life Scale (SSQOL), and the total quality of life score was calculated, a higher score indicates that the patient has a better quality of life.

  2. The National Institutes of Health Stroke Scale

    Time frame: 24 hours before discharge, 3, 6, 9 and 12 months

    The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS), is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke and aid in planning post-acute care disposition.

  3. Stroke Recurrence

    Time frame: 1 year

    Stroke recurrence (radiologically and clinically confirmed) within 1 year

  4. Drug Related Problem

    Time frame: 1 year

    Determination of drug-related problems (DRP) using Pharmaceutical Care Network Europe (PCNE) Version 9.1. The basic classification has 3 primary domains for problems, 9 primary domains for causes and 5 primary domains for Planned Interventions, 3 primary domains for level of acceptance (of interventions) and 4 primary domains for the Status of the problem.

Sponsors and collaborators

Lead sponsor

Marmara University

Other

Registry information

Official study title

Investigation of the Effects of Pharmaceutical Care Provided by a Clinical Pharmacist on Stroke Patients

Important dates

Study start
2021
Primary completion
2022
Study completion
2023
First posted
Nov 13, 2023
Registry last updated
Nov 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.